William B. Jones, Senior Vice President of Pharmaceutical Development at Corvus Pharmaceuticals, discusses how Lonza’s reputation for quality and its experience with antibodies were the driving forces in his company’s selection of CDMO for its CPI-006 antibody program, which is currently under development as an oncology drug and investigation as a therapeutic for immune disorders and infectious diseases.

You may also be interested in:
Mammalian
Cell Line Development
Clinical Supply Services
Mammalian Expression Technologies
Read this article
View now
Latest briefing from the Knowledge Center
Lonza_Bend_EarlyPhaseLab33
Article
Streamlining early phase drug development with continuous flow technologies
As small molecule complexity increases, early-stage development faces new challenges that demand...
Poster
Designing a Plug-and-Play System to Produce Engineered Extracellular Vesicles
Extracellular vesicles (EVs), including exosomes, are being studied extensively and have emerged as...
Poster
Plasmid Engineering and Process Development to Improve Self-Complementary AAV Productivity
Self-complementary AAV (scAAV) vectors were developed by mutating one of the ITRs to form...
Poster
Development of high-performing stable producer cell lines for therapeutic AAV vector manufacturing
Attributed to their safety profiles and transduction efficiencies, recombinant Adeno-associated...
Poster
Large-Scale High Titer Lentiviral Production Using Lonza's Suspension Transient Transfection...
Lentivirus vector (LVV) is a major player in cell and gene therapies. It efficiently transduces both...
Poster
Adeno-associated virus characterization using nanopore long read sequencing and analysis
Recombinant adeno-associated virus (rAAV) has become a leading vector for in vivo gene delivery. The...
Poster
Novel synthetic production phase promoter for enhanced titre, product quality and expression...
In this scientific poster, we demonstrate the development of a novel synthetic gene promoter...
Dolphin expansion rendering
Interview
Q&A on large-scale commercial expansion at Lonza's Stein facility
Are you a biopharmaceutical or biotech professional looking to stay ahead in the industry? Download...
Technical/Service brief
Novel synthetic fusion promoter for improved GS-CHO expression of biotherapeutics
Historically, advancements in CHO-based recombinant protein production have been driven...
Bend inhalation images
White paper
Navigating the development of dry powder for inhalation
Interest in pulmonary/nasal routes for local delivery has significantly increased over the last...
White paper
Innovations in linking rational design and material-sparing strategies for enabled intermediates and...
Did you catch our insightful webinar on Linking rational design and material-sparing strategies for...
Presentation (on-demand)
Challenging your AAV productivity and packaging efficiencies through a validated platform
AAV transient and stable cell line platforms represent a leap into next-generation technologies that...